QDEL, US2197981051

J.P. Morgan keeps USD 12.00 target for QuidelOrtho stock, 13.92 percent below price

Published on 10/15/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 630.90 million in the second quarter of 2026. QuidelOrtho stock costs EUR 12.37 on October 15, 2026 at 8:41 p.m. CEST, up 0.53 percent versus the Nasdaq prior close.

Analyst target and earnings date

J.P. Morgan analyst Casey Woodring kept a Sell rating and set a USD 12.00 target on October 14, 2026.
QuidelOrtho generated USD 630.90 million in revenue in the second quarter of 2026.
QuidelOrtho stock costs EUR 12.37 at Lang & Schwarz on October 15, 2026 at 8:41 p.m. CEST, up 0.53 percent versus the Nasdaq prior close of October 14, 2026.
QuidelOrtho is estimated to report third-quarter 2026 results on November 4, 2026.

QDEL, US2197981051, Illustration mit AI erstellt.

J.P. Morgan analyst Casey Woodring maintained a Sell rating on QuidelOrtho and set a USD 12.00 price target on October 14, 2026, according to Markets Insider. Against the USD 13.94 Nasdaq price, the target is 13.92 percent below the price. QuidelOrtho stock was at EUR 12.37 at Lang & Schwarz on October 15, 2026 at 8:41 p.m. CEST, up 0.53 percent versus the Nasdaq prior close of October 14, 2026.

Revenue reached USD 630.90 million

QuidelOrtho reported USD 630.90 million in revenue for the quarter ended June 28, 2026, compared with USD 613.90 million a year earlier. The company also reported a GAAP net loss of USD 92.90 million, narrower than the USD 255.40 million loss in the year-ago quarter, according to Markets Insider.

Price position and valuation

The Nasdaq-listed stock's USD 9.92 to USD 35.58 52-week range places the current USD 13.94 quote 60.82 percent below its high and 40.53 percent above its low as of October 15, 2026. Its year-to-date performance was minus 51.44 percent as of October 14, 2026, while the market capitalization was USD 956.1 million on October 15, 2026.

QuidelOrtho's estimated third-quarter 2026 earnings announcement is November 4, 2026, after the market close, with a conference call scheduled for 5:00 p.m. ET, according to MarketBeat. The same source lists expected revenue of USD 627.83 million and expected earnings per share of USD 0.2023 for the quarter.

Comparison with peers

QuidelOrtho: plus 0.53 percent, P/E minus 0.90, market capitalization USD 956.1 million
CONMED (NYSE, USD): plus 5.27 percent, P/E 25.54, market capitalization USD 1.4 billion
Haemonetics (NYSE, USD): minus 0.78 percent, P/E 58.92, market capitalization USD 5.5 billion

Listing and reporting dates

QuidelOrtho is registered on the Nasdaq Stock Market under ticker QDEL, as shown in a September 23, 2026 filing with the SEC. Its latest reported quarter ended June 28, 2026, and the next estimated reporting date is November 4, 2026.

Stock snapshot

For investors, the key tension is visible in the numbers: second-quarter revenue increased by USD 17.00 million year over year, while the USD 12.00 J.P. Morgan target remains below the USD 13.94 Nasdaq price. The estimated November reporting date provides the next scheduled point for assessing revenue and earnings expectations. The further course of trading is shown by the continuously updated real-time quote of QuidelOrtho stock.